​AAC​R Science Series at the FDA July 26, 2019: Highlights of the AACR Annual Meeting 2019


Elizabeth M. Jaffee, MD, Deputy Director, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center; Dana and Albert "Cubby" Broccoli Professor of Oncology; AACR President (2018-2019); Baltimore, Maryland

Dr. Jaffee will present scientific highlights of the AACR Annual Meeting 2019. Following the lecture, a Q&A session will take place.


July 26, 2019


11 a.m. - noon

Event Flyer.

Accreditation Statement

The American Association for Cancer Research (AACR) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education activities for physicians.

Credit Designation Statement

AACR has designated this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. 

Claiming (CME) Credit

Physicians and other health care professionals seeking AMA PRA Category 1 Credit(s)TM for this live continuing medical education activity must complete the online CME Request for Credit Survey by Monday, Sept 6, 2019. Certificates will only be issued to those who complete the survey. Your CME certificate will be sent to you via email after the completion of the activity.

Statement of Educational Need, Target Audience, and Learning Objectives

Rapid advances in basic oncology research necessitate equally rapid advances in the regulatory environment at the U.S. Food and Drug Administration such that the novel therapies and technologies for detection, prevention, and treatment of cancer being developed in our nation's research laboratories can be evaluated for their safety and efficacy based on the best current scientific knowledge.

Expert insight and analysis of these scientific breakthroughs will provide the regulatory staff at FDA with the skills and knowledge needed to evaluate new therapeutics and other medical products submitted for review to the agency.

After participating in this CME activity, physicians should be able to:

  • Articulate recent scientific advances in cancer research presented at the AACR Annual Meeting 2019.
  • Understand the latest research findings regarding therapies and treatment options, including immunotherapy and combination therapies, in a variety of cancer types to improve patient outcomes.

Disclosure Statement

In compliance with the standards set by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of the American Association for Cancer Research (AACR) that the information presented at CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, the AACR has provided information that planning committee members, speakers, and abstract presenters have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this CME activity. 

Speakers/Planners have the following to relationships to disclose.  Relationship types are abbreviated as follows: E, Employee of listed company, G, Grant/research support recipient, A, Advisor or review panel member, C, Consultant, S, Stock Shareholder, SB, Speakers’ Bureau, H, Honoraria, O, Other.

Ronald ArthurAACRNo RelationshipsStaff
Elizabeth JaffeeJohns Hopkins Univ.Aduro Biotech, Amgen, BMS, Genocea, Adaptive Biotech, DragonFly, Medimmune, CSTONE, Hertix, Corvus
Sarah Martin AACRNo Relationships Staff
Richard PazdurFDANo Relationships Program Com.
Jon RetzlaffAACRNo RelationshipsStaff
Marc TheoretFDANo Relationships Program Com.

Contact Information

Please contact the Office of CME at 215-440-9300 or